A pharmacokinetic-pharmacodynamic model for neuromuscular blocking agents to predict train-of-four twitches

被引:2
|
作者
Eleveld, DJ [1 ]
De Haes, A [1 ]
Proost, JH [1 ]
Wierda, JMKH [1 ]
机构
[1] Res Grp Expt Anesthesiol & Clin Pharmacol, NL-9700 RB Groningen, Netherlands
关键词
neuromuscular relaxants; pharmacokinetics; models; computers; train-of-four stimulation;
D O I
10.1023/A:1024430413262
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The train-of-four (TOF) stimulation pattern consists of 4 stimuli (T1, T2, T3, and T4) at 2 Hz, and is used in daily anesthesiological practice to determine the degree of relaxation caused by muscle relaxants. At a surgical levels of relaxation the degree of relaxation can be estimated by counting the number of "measurable'' or "visible'' muscular reactions to the 4 stimuli in the TOF stimulation pattern (TOF count). During recovery relaxation can be estimated by calculating the TOF ratio (T4/T1). Bartkowski and Epstein described a pharmacokinetic-pharmacodynamic (PK-PD) model to predict TOF ratio by modifying and extending the PK-PD model as described by Sheiner to use a hypothetical distributed effect compartment described by a median equilibration rate constant and a dispersion parameter. We extended the Bartkowski and Epstein PK-PD model to simulate all four TOF twitches by including EC50 terms for T2 and T3. We fit this model to data from the pig and compared the results to fitted models using separate PD models for each TOF twitch ( extended Sheiner model). The extended Bartkowski and Epstein model fit the twitch height data from all four TOF twitches better than the extended Sheiner model and has fewer parameters.
引用
收藏
页码:105 / 118
页数:14
相关论文
共 50 条
  • [1] A Pharmacokinetic–Pharmacodynamic Model for Neuromuscular Blocking Agents to Predict Train-of-Four Twitches
    Douglas J. Eleveld
    Ann De Haes
    Johannes H. Proost
    J. Mark K. H. Wierda
    Journal of Pharmacokinetics and Pharmacodynamics, 2003, 30 : 105 - 118
  • [2] Physicochemical properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic relationship
    Roy, JJ
    Varin, F
    BRITISH JOURNAL OF ANAESTHESIA, 2004, 93 (02) : 241 - 248
  • [3] Reversal of Neuromuscular Blockade with Sugammadex at the Reappearance of Four Twitches to Train-of-four Stimulation
    Pongracz, Adrienn
    Szatmari, Szilard
    Nemes, Reka
    Fuelesdi, Bela
    Tassonyi, Edoemer
    ANESTHESIOLOGY, 2013, 119 (01) : 36 - 42
  • [4] Pharmacokinetic-Pharmacodynamic Model for the Reversal of Neuromuscular Blockade by Sugammadex
    Ploeger, Batt A.
    Smeets, Jean
    Strougo, Ashley
    Drenth, Henk-Jan
    Ruigt, Ge
    Houwing, Natalie
    Danhof, Meindert
    ANESTHESIOLOGY, 2009, 110 (01) : 95 - 105
  • [5] Train-of-four to monitor neuromuscular blockade?
    Sessler, CN
    CHEST, 2004, 126 (04) : 1018 - 1022
  • [6] A pharmacokinetic-pharmacodynamic model for chemoprotective agents against malaria
    Cherkaoui-Rbati, Mohammed H.
    Andenmatten, Nicole
    Burgert, Lydia
    Egbelowo, Oluwaseun F.
    Fendel, Rolf
    Fornari, Chiara
    Gabel, Michael
    Ward, John
    Mohrle, Jorg J.
    Gobeau, Nathalie
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (01): : 50 - 61
  • [7] Neuromuscular blocking effects and train-of-four fade with cisatracurium: comparison with other nondepolarising relaxants
    Carroll, MT
    Mirakhur, RK
    Lowry, DW
    McCourt, KC
    Kerr, C
    ANAESTHESIA, 1998, 53 (12) : 1169 - 1173
  • [8] The Duration of Residual Neuromuscular Block After Administration of Neostigmine or Sugammadex at Two Visible Twitches During Train-of-Four Monitoring
    Illman, Hanna L.
    Laurila, Paivi
    Antila, Heikki
    Meretoja, Olli A.
    Alahuhta, Seppo
    Olkkola, Klaus T.
    ANESTHESIA AND ANALGESIA, 2011, 112 (01): : 63 - 68
  • [9] STRUCTURE-PHARMACODYNAMIC-PHARMACOKINETIC RELATIONSHIPS OF STEROIDAL NEUROMUSCULAR BLOCKING-AGENTS
    WIERDA, JMKH
    PROOST, JH
    EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 1995, 12 : 45 - 54
  • [10] A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc
    Rosario, MC
    Jacqmin, P
    Dorr, P
    van der Ryst, E
    Hitchcock, C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (05) : 508 - 519